Skip to main content
main-content

memo - Magazine of European Medical Oncology OnlineFirst articles

12.06.2019 | case report Open Access

Immunotherapeutic approach to a case of advanced hepatoid adenocarcinoma of the lung

Hepatoid adenocarcinomas (HAC), first described in 1985 by Ishikura et al. [ 1 ], are a rare type of extrahepatic alpha-fetoprotein secreting tumor with hepatocellular carcinoma (HCC) like morphology. Since that time, only 33 cases of HAC of the …

Autoren:
Anthony El Khoury, Marc El Khoury, Russel De Luca

12.06.2019 | case report

Head and neck Langerhans cell histiocytosis: two case reports and review of the literature

Langerhans cell histiocytosis (LCH) is an inflammatory neoplasia of myeloid precursor cells driven by mutations in the mitogen-activated protein kinase (MAPK) pathway. It can present as single or multisystem LCH. It occurs in 0.5–5.4 per million …

Autoren:
Dr. Ilson Sepúlveda, Ignacio Mendoza, Romina Novoa, Geraldine Ayres, Nadia Inostroza, J Patricio Ulloa, Francisco Rivas-Rodriguez

12.06.2019 | short review Open Access

Resistance to anti-hormonal therapy in prostate cancer

Advanced stage prostate cancer is frequently treated with androgen receptor antagonists. Improvement in patients’ survival has been achieved with the anti-androgen enzalutamide. However, there may be an increasing number of point mutations of the …

Autor:
M.D. Professor Zoran Culig

05.06.2019 | short review Open Access

Whom to screen? A view on lung cancer screening from the pneumologist’s perspective

The benefits of screening programs are highly dependent on risk group definition. This is especially true for lung cancer screening. Results from the National Lung Cancer Screening Trial (NLST) and the NELSON trial (Dutch/Belgian randomised lung …

Autoren:
Malte Asshoff, Günter Weiss, Ivan Tancevski

29.05.2019 | original report

Response assessment in non-small cell lung cancer immunotherapy: initial experiences in utilizing FDG PET/CT and the PD-1 blocker nivolumab

Non-small cell lung cancer (NSCLC) accounts for about 85% of all diagnosed lung cancers and at initial diagnosis nearly 70% of all patients suffer from locally advanced or metastatic disease [ 1 , 2 ]. Accordingly, most patients require systemic …

Autoren:
Diego Kauffmann-Guerrero, Andreas Schindler, Amanda Tufman, Zulfiya Syunyaeva, Thomas Pfluger, Rudolf Maria Huber, Frank Berger, Kathrin Kahnert

23.05.2019 | Correction

Correction to: Seasonal fever for 11 years! A presentation of hemophagocytic lymphohistiocytosis secondary to marginal zone lymphoma

Correction to: memo 2019 https://doi.org/10.1007/s12254-019-0487-4 The original version of this article unfortunately contained a mistake.The spelling of the last author’s name is “Prerna Mewawalla”.The original article has been … …

Autoren:
MD Abhishek Chaturvedi, MD Muhammad Salman Faisal, MD Ahmed Khattab, MD Joan Devine, MD Dr. Prerna Mewawalla

17.05.2019 | short review Open Access

Update in thrombosis and hemostasis: ASH meeting 2018

In the field of thrombosis and hemostasis the focus was laid on the prophylaxis and treatment of venous thromboembolism in patients with active cancer during this years’ meeting of the American Society of Hematology (ASH) in San Diego. The …

Autor:
MD Clemens Feistritzer

17.05.2019 | short review Open Access

Lung cancer screening from the oncologist’s perspective

How does lung cancer treatment benefit from the NELSON trial

With the release of the survival results from the NELSON lung cancer screening trial there is now additional evidence that low-dose computed tomography (LDCT) screening leads to a reduction of lung cancer mortality in high-risk individuals. These …

Autoren:
MD. PhD. Florian Kocher, MD Georg Pall

17.05.2019 | short review Open Access

Resistance to immune checkpoint inhibitors. Next steps and combinational approaches

Immuno-oncology and in particular checkpoint inhibitor (CPI) treatment has become a novel promising cancer therapy strategy in recent years. However, still a minority of patients respond to checkpoint blockade. Primary and secondary resistance to …

Autor:
MD Thorsten Fuereder

10.05.2019 | short review Open Access

Challenges in implementation of lung cancer screening—radiology requirements

Implementation of lung cancer screening is a challenge for radiology. The present short review summarizes major requirements which are needed to ensure high rates of diagnostic accuracy and appropriate protocols for follow-up and invasive work-up.

Autor:
MD, PD, MSc, EBIR Gerlig Widmann

02.05.2019 | obituary

Obituary for Professor Michael Steurer

Autor:
PD Dr. Alexander Egle

26.04.2019 | case report

Seasonal fever for 11 years! A presentation of hemophagocytic lymphohistiocytosis secondary to marginal zone lymphoma

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of excessive inflammation and immune activation. The syndrome can be triggered by multiple events that disrupt immune homeostasis, including infection, autoimmune diseases, and lymphoma.

Autoren:
MD Abhishek Chaturvedi, MD Muhammad Salman Faisal, MD Ahmed Khattab, MD Joan Devine, MD Dr. Prerna Mewawalla

18.04.2019 | short review Open Access

Resistance in gastrointestinal stromal tumors

The approval of imatinib for the treatment of patients with gastrointestinal stromal tumor has (GIST) revolutionized the treatment in the adjuvant setting and metastatic disease. Imatinib is an inhibitor of the receptor tyrosine kinases KIT and …

Autoren:
Andreas Seeber, Alexander Perathoner, Florian Kocher

18.04.2019 | short review

Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in mutated non-small cell lung cancer: new avenues and strategies to overcome resistance

The most common driver mutation in non-small cell lung cancer (NSCLC) is found within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). It commonly affects younger, female, and non-smoking patients. To date, there are five …

Autor:
Dr. Gudrun Absenger

03.04.2019 | editorial

memo—publisher’s report 2018

Autor:
Dr. Alois Sillaber

02.04.2019 | short review Open Access

Tobacco control: prevention and cessation in Europe

Reasons for high smoking prevalence in Europe compared to Australia and North America are low prices of tobacco adjusted for purchasing power and poor smoke-free legislation and enforcement in Central and Eastern Europe. High rates of passive …

Autor:
Prof. Manfred Neuberger

20.03.2019 | special report Open Access

Direct oral anticoagulants: a treatment option in oncological patients

Venous thrombosis and pulmonary embolism are common complications in patients with active cancer. For many years low molecular weight heparins (LMWH) have been the preferred treatment option for cancer patients, because of their superiority over …

Autoren:
Johannes B. Jaeger, Thomas Jaeger, Ass. Prof. Priv. Doz. Dr. Clemens Feistritzer

21.02.2019 | educational

Educational no.5: next-generation gene panel sequencing

Next-generation sequencing allows the simultaneous interrogation of a large number of genomic targets and is therefore highly suitable for situations, in which mutations in many different genes may have a clinical impact. This short educational …

Autor:
Wolfgang Kranewitter

21.02.2019 | review Open Access

Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer

Ovarian cancer (OC) is the foremost lethal gynaecologic malignancy and among the top five deadliest cancers in women. Current treatment comprises a combination therapy of surgery, platinum-based chemotherapy and anti-vascular endothelial growth …

Autoren:
MD, PhD Verena Wieser, MD, PhD Christian Marth

29.01.2019 | case report

Solitary scalp metastatic lesion as a sign of breast cancer recurrence—a case report

Being the most commonly diagnosed cancer in women, breast cancer is the second leading cause of cancer deaths among women in the United States [ 1 ]. With an incidence exceeding 20%, metastatic cutaneous lesions are more often found in women with …

Autoren:
MD Ahmed A. M. Abdelhafeez, MD Wael Ibrahim, MD Wessam Elsherief